Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Austria Belgium Czechia Denmark France Germany +9
  • A Study Testing BNT329 Safety and Effectiveness in Patients With Advanced Solid Tumors That Express the CA19-9 Tumor Marker

    Recruiting

    2 1 1
    Germany Spain
  • A Study of Olaparib Maintenance Treatment for Patients with Metastatic Pancreatic Cancer That Responded to First-Line Chemotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy
  • A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

    Recruiting

    2 1 1 1
    France
  • Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Germany
  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Belgium France Italy Spain
  • Evaluating 68Ga-FAPI-46 PET/CT Scanning for Improved Diagnosis in Patients with Pancreatic Cancer or Bile Duct Cancer Eligible for Curative Treatment

    Recruiting

    2 1 1 1
    France
  • Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

    Recruiting

    2 1 1
    Investigated Diseases:
    France
  • Study on [18F]FAPI-74 for Better Cancer Imaging in Patients with Esophagogastric and Pancreatic Cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    Belgium
  • Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    Denmark Germany The Netherlands Sweden